|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A company incorporating bits of defunct UK multinational Imperial Chemical Industries sends a US suitor packing. Then it spends years coaxing its shares back towards the offer price. It could be AstraZeneca. ...
Analysts at Citi hold a bullish rating on Merck & Co., Inc. (NYSE: MRK ). The firm's Andrew Baum upgraded Merck's stock from Neutral to Buy "for the first time," with a price target boosted from ...
U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018. The medicine, which is being jointly developed and marketed with Merck under a deal struck in July, is the first poly ADP-ribose polymerase (PARP) drug to be considered for use outside ovarian cancer. Lynparza is also being tested in prostate and pancreatic cancers, the two companies said on Wednesday.
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.
(Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ...
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.
Pharma companies are recruiting technologists to help speed up their drug discovery and development processes.
The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...
AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Pascal Soriot is the first to recognise that a pharmaceutical company must take risks if it is to find the next transformative medicine. "It would be much simpler to sell toothbrushes and toothpastes ...
Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.
There is a big difference between a cold and the flu - and it is a distinction on which drugmakers have long relied when selling throat lozenges and fortified lemon drinks over the counter for one condition ...
As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.
GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio.
Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.
HIV products reported a 29.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, driven by the strong performances of Tivicay and Triumeq.